Table 2 Correlations between NOVA1 expression and clinicopathological factors in lung cancers
From: NOVA1 promotes NSCLC proliferation and invasion by activating Wnt/β-catenin signaling
N | NOVA1 Negative | NOVA1 Positive | P-value | |
|---|---|---|---|---|
Age | ||||
< 60 | 48 | 25 (52.1%)) | 23 (47.9%)) | 0.597 |
≥ 60 | 97 | 46 (47.4%) | 51 (52.6%) | |
Gender | ||||
Male | 100 | 45 (45.0%) | 55(55.0%) | 0.154 |
Female | 45 | 26(57.8%) | 19(42.2%) | |
Histological type | ||||
Adenocarcinoma | 90 | 43(47.8%) | 47(52.2%) | 0.714 |
Squamous cell carcinoma | 55 | 28(50.9%) | 27(49.1%) | |
Differentiation | ||||
Well-moderate | 108 | 59(54.6%) | 49(45.4%) | 0.020 |
Poor | 37 | 12(32.4%) | 25(67.6%) | |
TNM stages | ||||
I-II | 93 | 55(59.1%) | 38(40.9%) | 0.001 |
III-IV | 52 | 16(30.8%) | 36(69.2%) | |
T stage | ||||
T1 | 24 | 19(79.2%) | 5(20.8%) | 0.001 |
T2-T4 | 121 | 52(43.0%) | 69(57.0%) | |
Lymph node metastasis | ||||
Negative | 76 | 49(64.5%) | 27(35.5%) | 0.000 |
Positive | 69 | 22(31.9%) | 47(68.1%) | |
β-catenin status | ||||
Negative | 43 | 28(65.1%) | 15(34.9%) | 0.012 |
Positive | 102 | 43(42.2%) | 59(57.8%) | |